Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania, bringing the company’s total to nine centers in Central & Eastern Europe and a total network of 25 across Europe and Africa.
The population of Central and Eastern Europe exceeds that of either the US or the five largest Western European markets combined, and it also has excellent healthcare professionals, according to the U.K.-headquartered recruitment specialist.
“This will help us to provide much greater support to the global pharmaceutical industry,” noted CEO Christophe Berthoux. “Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region.”
The new Polish facility is the company’s largest research center in the world. It occupies 1000 m2 at Beniowskiego Street in Gdansk. Magdalena Przekwas-Jaruchowska, M.D., the facility’s director, oversaw the opening ceremony, which included representatives from the local authority, the British Embassy, the medical university and patients’ associations.
Romania’s new 820 m2 center is based in Bucharest, which has a population of two million. The country has been part of Synexus’ development plans since early 2000, as the total population is over 20 million and the number of new clinical trials granted approval during the last five years is at least 200, according to the company.
In Sofia, Bulgaria, the total area of the new center is 650 m2, and it has eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This facility aims to offer its patients access to new drugs in the fields of pulmonology, rheumatology, neurology, endocrinology, cardiology, gastroenterology and dermatology.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.